What is HC Wainwright’s Estimate for VolitionRX Q2 Earnings?

VolitionRX Limited (NYSEAMERICAN:VNRX) – HC Wainwright upped their Q2 2026 earnings per share (EPS) estimates for VolitionRX in a research report issued on Thursday, April 2nd. HC Wainwright analyst Y. Chen now expects that the medical research company will earn ($0.03) per share for the quarter, up from their previous forecast of ($0.04). HC Wainwright currently has a “Buy” rating and a $1.00 target price on the stock. The consensus estimate for VolitionRX’s current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for VolitionRX’s Q4 2026 earnings at ($0.02) EPS and FY2026 earnings at ($0.11) EPS.

Separately, D. Boral Capital reissued a “buy” rating and set a $3.00 price target on shares of VolitionRX in a research report on Thursday, March 26th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $2.33.

VolitionRX Trading Down 0.7%

NYSEAMERICAN:VNRX opened at $0.17 on Tuesday. The firm has a market capitalization of $26.61 million, a price-to-earnings ratio of -0.76 and a beta of 1.33. VolitionRX has a 1-year low of $0.15 and a 1-year high of $0.94. The business’s fifty day moving average price is $0.21 and its 200 day moving average price is $0.32.

VolitionRX (NYSEAMERICAN:VNRX) last announced its earnings results on Tuesday, March 31st. The medical research company reported ($0.05) EPS for the quarter, meeting the consensus estimate of ($0.05). The company had revenue of $0.45 million for the quarter, compared to analysts’ expectations of $0.71 million.

Institutional Investors Weigh In On VolitionRX

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Virtu Financial LLC raised its stake in shares of VolitionRX by 166.6% during the 4th quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock worth $28,000 after purchasing an additional 67,848 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in shares of VolitionRX during the 4th quarter worth about $34,000. Jane Street Group LLC purchased a new stake in shares of VolitionRX during the 4th quarter worth about $28,000. Geode Capital Management LLC raised its stake in shares of VolitionRX by 9.8% during the 4th quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock worth $246,000 after purchasing an additional 85,816 shares in the last quarter. Finally, Armistice Capital LLC raised its stake in shares of VolitionRX by 10.4% during the 3rd quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after purchasing an additional 887,351 shares in the last quarter. 8.09% of the stock is owned by hedge funds and other institutional investors.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.